Wordt geladen...
Cardiovascular benefits of sodium-glucose cotransporter 2 inhibitors in diabetic and nondiabetic patients
Sodium-glucose cotransporter 2 inhibitors (SGLT2i) were developed as antidiabetic agents, but accumulating evidence has shown their beneficial effects on the cardiovascular system. Analyses of the EMPA-REG OUTCOME trial (Empagliflozin Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Pa...
Bewaard in:
| Gepubliceerd in: | Cardiovasc Diabetol |
|---|---|
| Hoofdauteurs: | , , |
| Formaat: | Artigo |
| Taal: | Inglês |
| Gepubliceerd in: |
BioMed Central
2021
|
| Onderwerpen: | |
| Online toegang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8028072/ https://ncbi.nlm.nih.gov/pubmed/33827579 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12933-021-01266-x |
| Tags: |
Voeg label toe
Geen labels, Wees de eerste die dit record labelt!
|